Correlation between tumour and serum beta 2m expression in patients with breast cancer

European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics
T KleinB Klein

Abstract

HLA class I antigens are composed of a major histocompatibility complex (MHC) encoded heavy chain that is associated non-covalently with a light chain beta-2 microglobulin (beta-2m). When the HLA complex is metabolized, beta-2m is shed into the serum. A large variety of human and experimental tumours have altered MHC class I expression. In a previous study we observed elevated mean beta-2m serum levels in breast cancer patients, as compared to controls. To study the relationship between tumour expression and serum levels, we examined 54 patients with breast cancer. Tumour beta-2m was determined by immunohistochemistry and serum levels by the ELISA technique. Of the 54 patients, 38 had low and 16 had high beta-2m expression on the tumour. There was a significant correlation between tumour beta-2m and serum beta-2m levels (P = 0.02), with patients whose tumours expressed high beta-2m having high serum beta-2m levels. There was an inverse correlation between tumour grade and tumour beta-2m expression which approached statistical significance (P = 0.06). These findings suggest that in a substantial number of patients the high serum levels derive from shedding of beta-2m from tumour cells. These levels may have implications for tumo...Continue Reading

References

Jul 1, 1977·Clinica Chimica Acta; International Journal of Clinical Chemistry·C TeasdaleL E Hughes
Nov 15, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·D PapaioannouJ Klassen
Jan 1, 1991·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·B KleinH Lurie
Feb 1, 1990·American Journal of Clinical Pathology·B KleinH Lurie
Sep 1, 1989·American Journal of Clinical Pathology·A del GiglioR Chammas
Jan 1, 1989·The Journal of Experimental Medicine·F Momburg, S Koch
Nov 15, 1985·Science·R S GoodenowR L Linsk
Apr 1, 1986·Journal of Immunogenetics·M A Lopez NevotF Garrido
Jan 1, 1987·British Medical Bulletin·H Festenstein
Aug 7, 1986·Nature·H Festenstein, F Garrido
Apr 1, 1986·Journal of Immunogenetics·R Garcia-EspejoJ Peña
May 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·P CresswellR T Kubo
Jun 12, 1981·Science·B Benacerraf
Jan 1, 1983·British Journal of Cancer·J A ChildL P Struthers
Nov 15, 1983·International Journal of Cancer. Journal International Du Cancer·S E KabawatA K Bhan
Jul 1, 1981·Journal of Clinical Pathology·K A FlemingJ O McGee

❮ Previous
Next ❯

Citations

Jun 28, 2000·Urologic Oncology·M Abdul, N Hoosein
Dec 5, 2000·International Journal of Cancer. Journal International Du Cancer·I GudmundsdóttirH M Ogmundsdóttir
Jun 4, 2008·Biological & Pharmaceutical Bulletin·Peramaiyan RajendranDhanapal Sakthisekaran
Aug 8, 2017·The British Journal of Sociology·Josh Ryan-Collins
Jul 1, 2017·Frontiers in Medicine·Christos P ArgyropoulosAntonios H Tzamaloukas
Feb 26, 2016·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anna E PrizmentCorinne Joshu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.